Premium
[IC‐P‐106]: PREDICTING PROGRESSION IN PRE‐DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE
Author(s) -
Loenhoud Anita C.,
Ossenkoppele Rik,
Wink Alle Meije,
Groot Colin,
Twisk Jos WR.,
Berckel Bart N.M.,
Barkhof Frederik,
Scheltens Philip,
Flier Wiesje M.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.2380
Subject(s) - dementia , alzheimer's disease neuroimaging initiative , cognitive reserve , neuroimaging , medicine , atrophy , cognitive decline , oncology , proportional hazards model , psychology , alzheimer's disease , biomarker , clinical dementia rating , cognition , disease , neuroscience , biochemistry , chemistry
(LOAD). Methods: We analyzed the available ADNI MRI and FDG-PET data of 99 amyloid-positive amnestic EO (44 MCI and 55 dementia), 186 amyloid-positive amnestic LO (109 MCI and 77 dementia) and 212 amyloid-negative cognitively normal (CN) subjects (Table 1). Amyloid positive status was determined using an F-AV-45 amyloid PET standard uptake value ratio (SUVR) 1.17 normalized to whole cerebellum. In order to study the extent of disease involvement, we compared the MRI, FDG-PET and amyloid PETof EOand LOMCI and DEM to the CN group using linear regression in SPM8 correcting for age, gender, and education. Additionally, in the MRI analyses, we controlled for intracranial volume and scan type. FWE correction for multiple comparisons was applied. Results:Demographic and amyloid burden comparisons of the diagnostic groups to CN can be seen in Tables 1 and 2. Direct